Isopropylphenidate: An ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 10, 2013, Pages 648-654

  Markowitz, John S ^a   Zhu, Hao Jie ^b   Patrick, Kennerly S ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CARBOXYLESTERASE; DOPAMINE TRANSPORTER; ESTER DERIVATIVE; ETHYLPHENIDATE; ISOPROPYLPHENIDATE; METHYLPHENIDATE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; NORADRENALIN UPTAKE; PROTEIN BINDING; RAT; SYNAPTOSOME; TRANSESTERIFICATION;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HYDROLYSIS; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84890713561     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0074     Document Type: Article

References (17)

1. Biederman J: Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 57:1215-1220, 2005.
2. Faraone SV, Sergeant J, Gillberg C, Biederman J: The worldwide prevalence of ADHD: Is it an American condition?World Psychiatry 2:104-113, 2003.
3. Greenhill LL, Pliszka S, Dulcan MK: Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. JAmAcad ChildAdolesc Psychiatry 41 (Suppl):26S-49S, 2002.
4. Imai T: Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173-185, 2006.
5. Kagan L, Hoffman A: Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 5:681-692, 2008.
6. Markowitz JS, Logan BK, Diamond F, Patrick KS: Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. J Clin Psychopharmacol 19:362-366, 1999.
7. Markowitz JS, Patrick KS: Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter? J Clin Psychopharmacol 28:S54-61, 2008.
8. Markowitz JS, Straughn AB, Patrick KS: Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23:1281-1299, 2003.
9. McConnell EL, Fadda HM, Basit AW: Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm 364:213-226, 2008.
10. Patrick KS, Caldwell RW, Ferris RM, Breese GR: Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241:152-158, 1987.
11. Patrick KS, Gonzalez MA, Straughn AB, Markowitz JS: New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv 2:121-143, 2005a
12. Patrick KS, Markowitz JS: Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 12:527-546, 1997.
13. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346-353, 2007.
14. PatrickKS, Williard RL, VanWert AL, Dowd JJ, Oatis JE, Jr., Middaugh LD: Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. J Med Chem 48:2876-2881, 2005b.
15. Ross MK, Crow JA: Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 21:187-196, 2007.
16. Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: Brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18:39-51, 2007.
17. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS: Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: Clinical significance and molecular basis. Am J Hum Genet 82:1241-1248, 2008.